Novartis and Guangzhou Pharma collaborate under HK-Macau drug scheme, showcase at CIIE
Novartis and Guangzhou Pharmaceutical have partnered under the 'Hong Kong-Macau Drug and Device Scheme' to advance radiopharmaceutical therapy access and clinical use. The collaboration was launched at the 9th China International Import Expo in Shanghai, with officials expressing hopes to deepen tie
Novartis and Guangzhou Pharmaceutical Co Ltd have agreed to cooperate under the framework of the 'Hong Kong-Macau Drug and Device Scheme' to promote cross-border access and clinical application of radiopharmaceutical therapy. The partnership was presented for the first time at the China International Import Expo (CIIE) in Shanghai.
The collaboration launch ceremony took place during the 9th CIIE in Shanghai. Han Zhenxiang, Deputy Director of the Guangzhou Municipal Commerce Bureau and full-time Deputy Director of the Guangzhou Investment Development Committee Office, said that he expects this cooperation to serve as a starting point for further deepening multi-field collaboration with global quality enterprises such as Novartis. He added that working with leading companies like Guangzhou Pharmaceutical would help attract more global innovative medical achievements to land in Guangzhou and be transformed in the Greater Bay Area.
Li Yao, President and Managing Director of Novartis China, stated that the 'Hong Kong-Macau Drug and Device Scheme' has built an important bridge between international medical innovation and clinical needs in the Greater Bay Area. He said that Novartis will continue to work with various parties to bring more global innovative achievements to China.